Gainers

• BiomX (AMEX:PHGE) shares rose 96.0% to $1.6 during Tuesday's regular session. The market value of their outstanding shares is at $8.2 million. The company's, Q1 earnings came out 4 days ago.
• Co-Diagnostics (NASDAQ:CODX) shares rose 86.78% to $9.47. The company's market cap stands at $18.5 million.
• QTREX Quantum (NASDAQ:QTEX) stock rose 77.48% to $1.29. The company's market cap stands at $31.6 million.
• Artelo Biosciences (NASDAQ:ARTL) shares rose 40.33% to $1.67. The company's market cap stands at $2.7 million.
• Outlook Therapeutics (NASDAQ:OTLK) shares increased by 37.04% to $0.42. The company's market cap stands at $37.4 million.
• NRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 30.12% to $4.19. The company's market cap stands at $116.6 million.

Losers

• Aditxt (NASDAQ:ADTX) shares decreased by 48.5% to $0.27 during Tuesday's regular session. As per the news, the Q1 earnings report came out 4 days ago.
• Polaryx Therapeutics (NASDAQ:PLYX) shares decreased by 34.73% to $2.35. The market value of their outstanding shares is at $170.4 million.
• Corbus Pharmaceuticals (NASDAQ:CRBP) stock fell 27.8% to $8.2. The market value of their outstanding shares is at $210.2 million.
• Quantum BioPharma (NASDAQ:QNTM) stock decreased by 22.73% to $7.14. The company's market cap stands at $59.1 million.
• MetaVia (NASDAQ:MTVA) shares decreased by 22.47% to $2.98. The company's market cap stands at $19.8 million.
• rYojbaba (NASDAQ:RYOJ) shares decreased by 21.53% to $3.92. The market value of their outstanding shares is at $56.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.